Although effective in treating an array of neurological disorders, antipsychotics are associated with deleterious metabolic side effects. Through high-throughput screening, we previously identified phenothiazine antipsychotics as modulators of the human insulin promoter. Here, we extended our initial finding to structurally diverse typical and atypical antipsychotics. We then identified the transforming growth factor beta (TGFb) pathway as being involved in the effect of antipsychotics on the insulin promoter, finding that antipsychotics activated SMAD3, a downstream effector of the TGFb pathway, through a receptor distinct from the TGFb receptor family and known neurotransmitter receptor targets of antipsychotics. Of note, antipsychotics that do not cause metabolic side effects did not activate SMAD3. In vivo relevance was demonstrated by reanalysis of gene expression data from human brains treated with antipsychotics, which showed altered expression of SMAD3 responsive genes. This work raises the possibility that antipsychotics could be designed that retain beneficial CNS activity while lacking deleterious metabolic side effects.
Introduction
An estimated 14.3 million Americans were taking antipsychotics in 2008, making them among the most prescribed drugs in the US. 1 Deleterious metabolic side effects, including obesity, insulin resistance, and diabetes, occur to some extent with almost all antipsychotics. 2, 3 Although their therapeutic effects are thought to be related to activation of dopamine and serotonin receptors in the CNS, 4 it has been unclear whether the metabolic side effects of antipsychotics are due to the modulation of those receptors or whether off-target effects might also be responsible. 3, [5] [6] [7] [8] [9] Previously, we found that phenothiazine-based antipsychotics modulated the insulin promoter. 10 Given the central role of insulin in metabolism and the regulation of its expression by molecules such as glucose, amino acids, and fatty acids, we hypothesized that insights into the metabolic side effects of antipsychotics could be achieved through uncovering the mechanism by which they affected the insulin promoter.
Here, we report that antipsychotics modulate the insulin promoter through activation of SMAD3, an important downstream effector of the transforming growth factor beta (TGFb) pathway. Activation occurred through a receptor distinct from those acted upon by TGFb itself, and also distinct from the neurotransmitter receptors responsible for the therapeutic effects of antipsychotics on CNS function. In vivo relevance of the finding was demonstrated by bioinformatic analysis of publically available gene expression data from brains of antipsychotic-treated schizophrenic patients. 11, 12 The TGFb pathway and SMAD3 in particular are highly associated with obesity, insulin resistance, and diabetes. [13] [14] [15] [16] [17] Obese individuals 18 and type II diabetics have higher serum levels of TGFb than normal controls, and healthy individuals with high serum TGFb are more likely to develop Type II diabetes. 13, 16 Also, mice with homozygous inactivating mutations of SMAD3 show enhanced glucose tolerance and are resistant to high-fat diet-induced obesity and insulin resistance. 17, 19 The finding that antipsychotics activate SMAD3 through a mechanism distinct from that responsible for the neurological effects of those drugs raises the possibility that antipsychotics could be designed that retain the beneficial neurological effects while lacking the deleterious metabolic side effects.
Materials and methods

For detailed descriptions of all techniques see Supplementary Methods.
Cell culture T6PNE cells 10 were maintained in RPMI-5.5 mM glucose supplemented with 10% fetal bovine serum and grown at 5% CO 2 , 37 1C. To induce E47 activity, 0.6 or 1 mM Tamoxifen (Sigma, St Louis, MO, USA) was added to culture media. PC3 Cells were cultured in F-12 media with 10% FBS, at 5% CO 2 , 37 1C. MCF7, HepG2, Panc-1, H157, WM35, LU 1205, and HeLa Cells were cultured in DMEM with 10% fetal bovine serum and grown at 5% CO 2 , 37 1C.
T6PNE Ins-green fluorescent protein (GFP) insulin promoter assay T6PNE cells were seeded at 1750 cells per well in clear bottom black 384-well plates (Greiner, Frickenhausen, Germany) with 0.6 or 1 mM Tamoxifen. Twenty-four hours later, compound or vehicle was added. Fortyeight hours after compound addition, cells were fixed with 4% formaldehyde. DAPI (0.167 mg/ml) was added to visualize nuclei. The plates were imaged on an IC 100 high-throughput microscope in the blue and green channels. Cytoshop software (Beckman Coulter, Brea, CA, USA) was used to determine the percent of cells in each well exhibiting green fluorescence above a threshold determined by a MATLAB algorithm, which is expressed as the fold change from vehicle treated control (fold change GFP þ cells) as previously described. 10 Significance was determined with a onetailed t-test.
Results
Both typical and atypical antipsychotics modulate the insulin promoter As phenothiazine antipsychotics have been supplanted to a large degree by the structurally diverse atypical antipsychotics, we extended our analysis of antipsychotic activity beyond the phenothiazines studied previously. 10 Despite the structural diversity of the antipsychotics tested, almost all modulated insulin promoter activity in T6PNE (Figure 1a,  Supplementary Figure 1 ). There was no clear relationship between the classification of a drug as typical or atypical and its activity in the assay. Ethopropazine Inhibitors were added at 0.5 and 5 mM, with each inhibitor being run in duplicate (only replicates at 5 mM are shown). In all, 10 inhibitors repressed the insulin promoter (m). Of the 10, 1, the TGFb R1 inhibitor SB-505124 (K), was a potent insulin promoter inhibitor in the absence, but not the presence of ethopropazine. (e) RT-PCR analysis of endogenous insulin gene expression. T6PNE cells were treated for 48 h with the indicated condition (n = 9). Error bars are s.e.m. * indicates P < 0.05 relative to DMSO control.
was the most potent, and as it is chemically stable we used it as the prototypical active antipsychotic. Also, as expected if the effects of antipsychotics on the insulin promoter in T6PNE are relevant to the metabolic side effects of the drugs, molindone and ziprasidone, which are not associated with strong metabolic side effects in patients [20] [21] [22] did not affect insulin promoter activity.
Neurotransmitter receptors targeted by antipsychotics are inactive in the insulin promoter assay As it is known that antipsychotics activate multiple neurotransmitter receptors 23, 24 and many of those are expressed in islets, 25 where they have important roles in b-cell function, 26 we hypothesized that the effect of antipsychotics on the insulin promoter was through a pathway involving the known neurotransmitter receptor targets of antipsychotics. To test this, we first analyzed gene expression data (GSE18821) 10 to determine which neurotransmitter receptor targets of antipsychotics were expressed in T6PNE cells, finding that many were expressed at approximately equal levels in T6PNE and primary human islets (Supplementary Figure 2A ). Specific receptor antagonists were then tested for activity on the human insulin promoter-eGFP transgene in T6PNE cells. None prevented ethopropazine from stimulating the insulin promoter, or altered insulin promoter activity in the absence of the drug (Figure 1b) , leading us to conclude that the target of the antipsychotics responsible for insulin promoter modulation was not one of the known neurotransmitter receptor targets responsible for their therapeutic benefit.
Antipsychotics signal to the insulin promoter downstream of the TGFbR1 kinase Given the negative results with known antipsychotic targets, we switched to an unbiased approach, screening the T6PNE insulin promoter assay with a diverse library of kinase inhibitors (Calbiochem Inhibitor), which has been used previously in high-throughput screens. 27 The rationale for this approach was that essentially all signaling pathways involve phosphorylation, and so we hoped to gain insight into the pathways being acted upon by antipsychotics by screening a library containing a large number of kinase inhibitors. The library was screened in the presence and absence of ethopropazine to ascertain kinase inhibitors with activity that was selectively affected by antipsychotics (Figure 1c, d) .
A total of 10 compounds repressed the insulin promoter in the absence of ethopropazine, (Figure 1c , m and K); other apparent repressors were cytotoxic false positives. One of the 10, SB-505124, an inhibitor of TGFb type 1 receptors, of which there are 7 family members (designated ALK1-7), 28 completely lost activity in the presence of ethopropazine (Figure 1d, K) . This indicates that ethopropazine is epistatic to the TGFb type 1 receptor kinase, signaling to the insulin promoter through the TGFb pathway at a point downstream. A dose-response study of the effect of SB-505124 demonstrated potent repression of the human insulin promoter-eGFP transgene with an IC50 of 0.34 mM (Supplementary Figure 3) , which was confirmed on the endogenous insulin gene in the absence, but not in the presence of ethopropazine, supporting the results with the transgene (Figure 1e ).
SB-505124 exhibits a strong preference for TGFb type I receptors ALK 4/5/7 over ALK 1/2/3/6, and has no or minimal activity on a panel of 27 other protein kinases at the highest concentration used in the kinase inhibitor screen (5 mM). 28 We examined the expression of the TGFb receptor family in T6PNE using gene expression microarray data, finding good concordance between the level of expression in T6PNE and primary human islets (GSE18821). 10 While ALK2 was the most highly expressed, ALK4, ALK5, and ALK7 were also present, consistent with the preferential activity against ALK4/5/7 exhibited by SB-505214.
Antipsychotics activate the TGFb pathway
We next tested if the major downstream mediators of the TGFb pathway, the SMAD transcription factors, were activated by antipsychotics. In the classical TGFb signaling pathway, receptor-regulated SMADs (R-SMADs) are phosphorylated by a TGFb type I receptor, promoting nuclear translocation and binding to the SMAD-binding element (SBE) CAGAC in promoters to modulate gene expression. 29 However, non-canonical SMAD activation is well described. 30 As expected, TGFb1 activated and SB-505124 inhibited the R-SMAD reporters SBE4-Luc 31 and CAGA12-Luc 32 ( Figure 2a and b), which contain multimerized sequence elements responsive to R-SMADs driving a luciferase reporter. 31 Ethopropazine activated R-SMAD reporter activity in both assays (Figure 2a and b) .
Next, we performed a structure-activity relationship (SAR) study on the SBE4-Luc reporter with the array of typical and atypical antipsychotics used previously ( Figure 2c ). Strikingly, the two SARs (insulin promoter versus SBE4-Luc reporter) were highly correlated (Pearson's correlation coefficient = 0.93, P = 0.00012) (Figure 2d ). This high correlation coefficient strongly supports a model in which antipsychotics signal to the insulin promoter through activation of the TGFb pathway.
Antipsychotics promote phosphorylation of SMAD3 but not SMAD2 As it is well established that R-SMADs are activated by phosphorylation, 33 and antipsychotics activated two R-SMAD reporters, we tested if antipsychotics promoted increased phosphorylation of the R-SMADs responsive to TGFb, SMAD2 and SMAD3. As expected, TGFb1 increased and SB-505124 decreased the levels of both phosphorylated SMADs assayed by immunoblot with phospho-specific antibodies ( (Figure 2g , h). These experiments led us to conclude that TGFb and antipsychotics differentially activate SMAD3 and SMAD2, and there must be distinct pathways by which antipsychotics and TGFb promote phosphorylation of R-SMADs.
SMAD3 is required for the effect of antipsychotics on the insulin promoter
If antipsychotics signal to the insulin promoter solely through SMAD3, then downregulation of SMAD3, but not SMAD2, by siRNA should ablate the effect of antipsychotics on the insulin promoter. We found this to be true; SMAD2 siRNAs did not affect the effect of antipsychotics on the insulin promoter, whereas those effects were almost completely ablated by a SMAD3 siRNA (Figure 3a ). We also found that SMAD3 overexpression, confirmed by immunoblot to result in a 2.1-fold increase in SMAD3 protein, enhanced insulin transcription (Figure 3d ), whereas SMAD3 siRNA potently inhibited the insulin promoter ( Figure 3a) .
TGFb inhibits the insulin promoter through downregulation of SMAD3 transcription
The fact that SB-505124 repressed insulin gene expression in T6PNE cells implies that there is a (e, g) Immunoblot analysis of phospho-SMAD levels. T6PNE cells were treated for 1 h with the indicated condition and a western blot was performed with antibodies towards total and pSMAD3 (e) or total and pSMAD2 (g), and HSP90. (f, h) Quantification of pSMAD3 (f) and pSMAD2 (h) protein levels demonstrated that antipsychotics increased pSMAD3, but not pSMAD2. The pSMAD intensity was divided by the total SMAD intensity (n = 3, blot shown is representative of 3 independent experiments). Error bars are s.e.m. * indicates P < 0.05 relative to DMSO control.
basal level of TGFb pathway activity in those cells, acting to stimulate promoter activity. This is consistent with the effects of SMAD3 siRNA and overexpression ( Figure 3) , and with previous data on TGFb pathway activation in b-cells. 15, 34, 35 However, TGFb1, TGFb2, and Activin A all exhibited dosedependent inhibition of the human insulin promotereGFP transgene (Supplementary Figure 4A-C) and the endogenous insulin promoter (Figure 1e) , with TGFb1 being the most potent. As it has been reported previously that TGFb1 can inhibit SMAD3 gene expression, 36, 37 we tested by quantitative RT-PCR the effect of TGFb1 on SMAD mRNA levels in T6PNE cells. TGFb1 induced a dramatic decrease in SMAD3 but not SMAD2 mRNA levels, whereas ethopropazine had no effect on either SMAD3 or SMAD2 mRNA (Figure 3b, c) . In addition, 48 h of treatment with TGFb but not ethopropazine, decreased SMAD3 protein levels assayed by immunoblot (Figure 3e ). Thus, in the acute 24 h setting of a transient transfection assay, the effect of TGFb1 on SMAD phosphorylation is dominant, whereas in the longer duration 48 h assay on insulin gene expression, its effect on SMAD3 gene expression predominates.
To determine the generality of the effect of TGFb on SMAD gene expression, we used the Pubmed Gene Expression Omnibus database to examine previous reports on the effect of TGFb in a variety of different cells. The vast majority of those studies found substantial effects of TGFb on SMAD3 (average fold change = À2.15), but not SMAD2 mRNA (average fold change = À0.31) (Supplementary Table 1 ).
Antipsychotics signal to the insulin promoter through modulation of E-box activity downstream of SMAD3 There are multiple mechanisms by which SMAD proteins could affect insulin promoter activity. Although the human insulin promoter contains a SMAD binding site, 38 the TGFb pathway has been shown to modulate E-box activity, 39 and SMAD proteins have been shown to interact directly with bHLH factors, 40, 41 suggesting that the effect of antipsychotics on the insulin promoter could also be at E-boxes. We showed previously that CDKN1C, the gene encoding p57Kip2, is regulated in T6PNE by a specific E-box in the promoter, resulting in co-regulation with the insulin gene in those cells. 10 As no SMAD-binding elements are present in the Kip2 promoter, we tested the effect of antipsychotics on Kip2 gene expression to specifically detect effects on E-box activity. Ethopropazine potently activated Kip2 transcription in T6PNE cells (Figure 4a ), as well as in T6PN cells (Figure 4b ), which express PDX1 and NeuroD1 and low levels of endogenous E47, but not E47 MER. 10, 42 T6PN was used to rule out the possibility that antipsychotics could be acting as agonists for the modified estrogen receptor, leading to activation of E47 by a physiologically irrelevant mechanism. Of significance, the SAR for the antipsychotics on Kip2 expression was highly correlated with their effect on insulin expression, as one would expect if the mechanisms by which the drugs affect the two promoters were the same (Figure 4c ). Similar to their effects on the insulin promoter, SB-505124 and TGFb1, decreased the level of Kip2 mRNA, whereas the effect of SB-505124 was blocked by ethopropazine ( Figure 4a ). SMAD3 siRNA potently inhibited Kip2 gene expression, whereas SMAD2 siRNA had no effect (Figure 4d ), demonstrating the specificity of regulation of E-box activity by SMAD3.
To confirm that the effects of antipsychotics were through the E-box directly and not any other sequence elements, we used a promoter-reporter construct, 4RTK-Luc, in which the luciferase reporter is under the control of a promoter consisting of multimerized E-box elements 5 0 of a thymidine kinase minimal promoter. 43 Antipsychotics activated 4RTK-Luc, whereas TGFb1 and SB-505124 repressed reporter activity (Figure 4e) , with antipsychotics being epistatic to the effect of SB-505124. Thus, all of the results are consistent with a model in which antipsychotic effects on the insulin promoter are mediated by activation of SMAD3, which then acts through E-boxes to affect gene expression.
Brain tissue from antipsychotic-treated schizophrenic patients shows gene expression patterns consistent with activated SMAD3
To determine whether the finding that antipsychotics activated the TGFb pathway in vitro was relevant to effects of antipsychotics in patients, we used a bioinformatic approach, taking advantage of published transcriptome data from schizophrenic patients treated with antipsychotics. In 2008, Mudge et al.
11 used RNASeq technology to study the pattern of gene expression in the brains of schizophrenic patients treated with antipsychotics compared with untreated control subjects. We utilized the web-based systems biology software NextBio (Cupertino, CA, USA) to reanalyze their data with a specific focus on the effect of antipsychotics on SMAD-responsive genes.
NextBio is a database comprising lists of genes sharing a common property such as possessing a particular transcription factor-binding site in their promoters, or being modulated in response to a particular intervention. It compares those lists with gene lists provided by the user and generates a statistical measure of the association between the two lists, expressed as a P-value and calculated using a 'running Fisher's test' algorithm. 44 To validate the NextBio algorithm with the Mudge et al., 11 dataset, we analyzed in NextBio the list of genes altered in all the antipsychotic treated patients compared with the healthy, untreated controls. Consistent with the conclusions of Mudge et al, 11 the Golgi apparatus and vesicle-mediated transport gene ontology lists were statistically significantly associated with the genes altered in the antipsychotic treated patients (Supplementary Table 2 , P = 0.00037 and 0.0089, respectively).
Next, we extracted lists of genes affected by particular antipsychotics from the Mudge et al., 11 dataset to determine whether they were statistically significantly similar to lists of genes containing particular transcription factor-binding sites in their promoters, with a focus on genes downstream of the TGFb pathway. Those lists came from an analysis done by Xie et al., 45 who used a genome-wide comparative analysis of gene promoter sequences across four species combined with the TRANSFAC dataset of transcription factor binding sites, 46 to identify all genes with promoter-binding sites for specific transcription factors, including SMAD1 and SMAD3 45 (Supplementary Table 4 ). When the data from all patients were considered together, the significance of the association between the list of genes altered in antipsychotic treated patients and the list of genes with SMAD3-binding sites in their promoters was marginal (P = 0.054, Supplementary Table 2 ). However, when we restricted the analysis to the patients taking the four antipsychotics (chlorpromazine, haloperidol, risperidone, and thioridazine) that were most active in the SMAD reporter assay (Figure 2c ), there was a highly significant association with SMAD3 responsive genes (P = 0.0096, Supplementary Table 2 ). To test the specificity of the association between our in vitro SAR and the in vivo effects of the drugs on genes containing SMAD3 sites in their promoters, we examined the effect of antipsychotics on genes containing SMAD1 sites, finding no association regardless of whether all antipsychotics or the four most potent in the in vitro assays were considered (P = 0.11 and 0.18, respectively, Supplementary Table  2) . This is important, as, while SMAD3 and SMAD1 are highly related, SMAD1 is an effector of BMP and not TGFb signaling. 47 As a further test of clinical relevance, we analyzed a second set of gene expression data from the brains of patients inflicted with schizophrenia who were treated with antipsychotics compared with healthy matched controls. 12 In this study, using microarrays rather than RNA-Seq, the number of altered genes declined almost to zero with increasing duration of illness. Focusing therefore on patients with short duration of illness, we found an increase in the statistical significance of the association between the genes with SMAD3-binding sites and the genes altered by antipsychotics when only the antipsychotics that were most potent in vitro were considered (0.043 vs 0.071 for all drugs (Supplementary Table 3 ).
Having shown in two independent sets of gene expression data from antipsychotic-treated patients, a correlation between the most active drugs in vitro with effects on SMAD3-responsive genes in vivo, we increased the granularity of the study by analyzing each antipsychotic individually, calculating the statistical association between the genes altered in each antipsychotic treated patient brain with SMAD3 or SMAD1-responsive genes. The values for each antipsychotic were averaged and plotted against the data from the SMAD reporter SAR (Figure 2c) . For SMAD3 regulated genes (Figure 5a) , the correlation of these two parameters was highly significant, with a Pearson's correlation coefficient of 0.89 (P = 0.0013), whereas for SMAD1 ( Figure 5B ) there was poor correlation (correlation coefficient = 0.42, P = 0.24). The striking and highly significant correlation between the insulin promoter and SMAD reporter data generated in vitro in T6PNE cells and transcriptome data generated by two independent groups in samples from patients with schizophrenia provides strong evidence that our finding of TGFb pathway activation by antipsychotics is clinically relevant.
Antipsychotics activate the TGFb pathway in only a subset of cell lines As antipsychotics and TGFb appear to act through distinct pathways that converge on SMAD3, we speculated that there might be cell lines in which antipsychotics and TGFb differ in their ability to activate SMAD3, owing to differential expression of proteins that act in the distinct pathways. If such cell lines could be found, they would be of great value in identifying pathway-specific components, facilitating the design of novel, non-diabetogenic antipsychotics. Thus, we examined published data on patterns of gene expression in cell lines treated with antipsychotics in vitro.
The Broad Connectivity Map (CMAP 2.0) is a database consisting of gene expression data from three cultured human cell lines treated with bioactive small molecules, including 13 antipsychotics. 48 Using this dataset, we performed the same Nextbio analysis used previously for the patient samples, calculating the significance of the association between genes altered by treatment with a specific antipsychotic and genes with SMAD3-binding sites in their promoters (a measure of whether antipsychotics are modulating SMAD3-responsive genes) and determining its correlation to the in vitro SMAD reporter SAR (Figure 5c The statistical analysis predicted that in PC3, but not MCF7 or HL-60 cells, antipsychotics should activate the SBE4 SMAD reporter. This proved true, ethopropazine activated the SMAD-responsive SBE4 reporter, in PC3 but not in MCF7 cells (Figure 5f ). However, TGFb exhibited the same pattern, suggesting that the defect in MCF7 was in a pathway leading to SMAD3 activation shared by antipsychotics and TGFb. MCF7 has been reported to be unresponsive to TGFb due to an effect of Notch4. 49 To determine whether cell lines with defects in a pathway specific to antipsychotic-mediated SMAD3 activation existed, we studied a panel of seven other cell lines. Similar to T6PNE and PC3, both ethopropazine and TGFb activated the SMAD reporter in the melanoma cell line LU-1205 (Figure 5f ). Similar to MCF7, WM35 was refractory to both ethopropazine and TGFb (Figure 5f ). However, in HepG2, H157, Panc-1, and HeLa cells, TGFb potently activated the SMAD reporter but antipsychotics were completely inactive, suggesting that a component unique to the pathway linking antipsychotics to SMAD3 activation is absent or defective in those cell lines (Figure 5f ).
Discussion
The major finding presented here is that antipsychotics activated SMAD3, a downstream effector of TGFb signaling, through a non-canonical pathway that involves neither the TGFb receptor complex nor the neurotransmitter receptors that are believed to be responsible for the therapeutic effects of antipsychotics. Our data support a model in which antipsychotics and TGFb signal to SMAD3 through independent pathways that converge downstream to activate SMAD3. Support for this comes from multiple lines of evidence. TGFb, but not antipsychotics, activated SMAD2 and repressed SMAD3 gene expression. Cell lines exhibiting potent SMAD activation by TGFb that were unresponsive to antipsychotics also indicates differences in the pathways acted on by TGFb and antipsychotics. Previously proposed mechanisms for the metabolic effects of antipsychotics are diverse, 3, 5, 6, 8, 50 but many postulate that their CNS effects resulted in increased appetite and hence weight gain. 8, 50 However, this could not be sufficient to account for all metabolic side effects, as a direct correlation between weight gain and diabetes in antipsychotic treated patients is often not seen. 20, 51, 52 The TGFb pathway is highly associated with obesity, insulin resistance, and diabetes. Higher levels of serum TGFb have been shown to predict the development of type II diabetes, 13, 16 and mice with genetic deletion of SMAD3 are resistant to high fat diet-induced obesity and insulin resistance. 17, 19 However, the effects of TGFb signaling are complex and indicate that the level of pathway activation needs to be maintained in a tightly regulated range. It has been reported that SMAD3 both enhances and inhibits insulin gene expression. 15, 35 Studies with transgenic models of TGFb inhibition in mouse b-cells suggest that TGFb signaling is required for insulin production and proper b-cell function, but studies of TGFb overexpression found that it led to b-cell dysfunction and hyperglycemia. 19, 34, 53 In vivo relevance of SMAD activation by antipsychotics came from analysis of two independent gene expression datasets from the brains of antipsychotictreated patients and normal controls. 11, 12 In both of those previous studies, antipsychotics were analyzed as a group, obscuring the effect of particular antipsychotics on the TGFb pathway, and neither identified TGFb signaling as being affected by antipsychotics. However, performing the analysis in light of the SAR of antipsychotic effects on the SMAD reporter produced a dramatically different picture, revealing a highly significant correlation between the effects of particular antipsychotics on SMAD3-responsive genes in patients and their effect on SMAD and insulin promoter activity in vitro.
If effects of antipsychotics on SMAD3 activation are responsible for the metabolic side effects of those drugs, one might predict that the drugs that have the greatest propensity to cause metabolic side effects would cause the greatest activation of SMAD3. In particular, first generation antipsychotics, that are often described as having a lower propensity to cause metabolic side effects, 54 were quite potent in their ability to activate SMAD3 in our assays. However, there are extensive inconsistencies in the literature on the relative propensity of antipsychotics to cause metabolic side effects 3,5-9 with part of the problem being that newer drugs have been more intensively studied in that regard. 55, 56 Also, it is well known that small perturbations of TGFb signaling can have large physiological effects, and the TGFb pathway has complex feedback loops 34, 57 potentially confounding such a correlation, particularly with drugs that are most effective at inducing SMAD3 activation. Finally, antipsychotics are often dose-limited by side effects, such as extra pyramidal symptoms and dyskinesias, which are related to dopamine D2 receptor blockade and are more common in first generation antipsychotics, such as chlorpromazine and haloperidol, while our in vitro assays were done at a dose determined by activity in cell lines. The effect of non-metabolic dose-limiting side effects in patients and the lack of precise dose information for the patients used in the genomic analyses used here could significantly affect the relationship between the reported incidence of metabolic side effects for a particular drug and our determination of its propensity to activate SMAD3. However, we did observe two antipsychotics that have consistently been found to have a weak or no association with obesity and diabetes, molindone and ziprasidone [20] [21] [22] were weak or inactive in the insulin promoter and SMAD reporter assays. These two antipsychotics fall into a structurally distinct class, containing dihydroindolone and indolinone cores, respectively, which are not found in the phenothiazines or any of the other typical or atypical antipsychotics.
The structural specificity of antipsychotics for effects on SMAD3 activation, combined with the data on the differential responsiveness of cell lines to antipsychotics, indicates that the effects of antipsychotics are mediated through a specific target that is affected by structural features of particular antipsychotics. On the basis of the known binding profile of antipsychotics, we hypothesized that the direct target of antipsychotics leading to SMAD3 activation was likely to be a GPCR. Unfortunately, attempts to use screening of siRNAs to GPCRs, in combination with gene expression data from the cell lines that responded or did not respond to antipsychotics, were unsuccessful in identifying an antipsychotic target that activated SMAD3. Some intracellular proteins and processes are also targeted by antipsychotics, including calmodulin, Protein Kinase C, and clathrinmediated endocytosis, 58, 59 but we found none to be involved in the signaling of antipsychotics to SMAD3.
The correlation between the propensity of particular antipsychotics to cause metabolic side effects and their ability to activate SMAD3 strongly suggests that the activity of antipsychotics on the TGFb pathway is a significant factor in causing those side effects. The fact that the neurotransmitter receptor targets of the antipsychotics relevant to treating psychosis are unrelated to modulation of the TGFb pathway opens the door to the possibility of developing antipsychotics that retain activity on the therapeutically beneficial neurotransmitter receptors, while not having effects on the TGFb pathway. Although such drug design efforts would be aided by the identification of the direct target of antipsychotics responsible for signaling to SMAD3, the availability of a sensitive assay for antipsychotic effects mediated by SMAD3 activation, that is, the insulin promoter assay in T6PNE cells, allows novel antipsychotics to be rapidly screened for their propensity to activate SMAD3. This has the potential to lead to optimized antipsychotics that retain a favorable profile of activity on the neurotransmitter receptors that are responsible for their clinical benefit, while lacking effect on the target that signals to the TGFb pathway.
